Select Publications

Boffa, D et al. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. 2017 January. DOI: 10.1158/1055-9965.EPI-17-0120 

Anantharaman, A et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer 201616:744 DOI: 10.1186/s12885-016-2758-3

Scher, H et al. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. 2016 November. DOI:/10.1016/j.eururo.2016.11.024

McDaniel AS, et al. Phenotypic diversity of circulating tumor cells in patients with metastatic castration-resistant prostate cancerBJU Int. 2016 Aug . doi: 10.1111/bju.13631. [Epub ahead of print]

Lowes, LE et al. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci. 2016 Sep ;17(9)

Scher, H et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncology. Advance Online Publication: 2016 June. DOI:10.1001/jamaoncol.2016.1828

Beltran, H et al. The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. 2016 March. DOI:10.1158/1078-0432.CCR-15-0137

Zhang et al. Detection and Characterization of Circulating Tumour cells in multiple myloma.  J Circ Biomark, 2016, 5:10. doi: 10.5772/64124

Beltran, et al. (2015) The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical Cancer Research. Author Manuscript Published OnlineFirst on December 15, 2015; DOI: 10.1158/1078-0432.CCR-15-0137

Punnoose, et al. (2015) PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. British Journal of Cancer, 1–9 | doi: 10.1038/bjc.2015.332

Werner, et al (2015) Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. J Circulating Biomarkers 4:3. doi: 10.5772/60725

Lu, et al. (2015) Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells. J Circulating Biomarkers. 4:4. doi:10.5772/60745

Interested in starting a project with Epic Sciences? Contact us

Up to date with Epic Sciences

All of Epic Sciences’ offerings can be included in your companion diagnostic assay to ensure the right treatment for the right patient at the right time. Request more information on CDx capabilities here:info@epicsciences.com